» Articles » PMID: 29126954

Quantitative Analysis of Kynurenine Aminotransferase II in the Adult Rat Brain Reveals High Expression in Proliferative Zones and Corpus Callosum

Overview
Journal Neuroscience
Specialty Neurology
Date 2017 Nov 12
PMID 29126954
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, acts as an endogenous antagonist of alpha7 nicotinic and NMDA receptors and is implicated in a number of neurophysiological and neuropathological processes including cognition and neurodegenerative events. Therefore, kynurenine aminotransferase II (KAT II/AADAT), the enzyme responsible for the formation of the majority of neuroactive kynurenic acid in the brain, has prompted significant interest. Using immunohistochemistry, this enzyme was localized primarily in astrocytes throughout the adult rat brain, but detailed neuroanatomical studies are lacking. Here, we employed quantitative in situ hybridization to analyze the relative expression of KAT II mRNA in the brain of rats under normal conditions and 6 h after the administration of lipopolysaccharides (LPSs). Specific hybridization signals for KAT II were detected, with the highest expression in the subventricular zone (SVZ), the rostral migratory stream and the floor of the third ventricle followed by the corpus callosum and the hippocampus. This pattern of mRNA expression was paralleled by differential protein expression, determined by serial dilutions of antibodies (up to 1:1 million), and was confirmed to be primarily astrocytic in nature. The mRNA signal in the SVZ and the hippocampus was substantially increased by the LPS treatment without detectable changes elsewhere. These results demonstrate that KAT II is expressed in the rat brain in a region-specific manner and that gene expression is sensitive to inflammatory processes. This suggests an unrecognized role for kynurenic acid in the brain's germinal zones.

Citing Articles

The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.

Stone T, Darlington L, Badawy A, Williams R Int J Mol Sci. 2024; 25(16).

PMID: 39201726 PMC: 11354734. DOI: 10.3390/ijms25169040.


scEWE: high-order element-wise weighted ensemble clustering for heterogeneity analysis of single-cell RNA-sequencing data.

Huang Y, Jiang H, Ching W Brief Bioinform. 2024; 25(3).

PMID: 38701413 PMC: 11066953. DOI: 10.1093/bib/bbae203.


Effects of Fenofibrate and Gemfibrozil on Kynurenic Acid Production in Rat Kidneys In Vitro: Old Drugs, New Properties.

Zakrocka I, Kocki T, Urbanska E, Zaluska W Life (Basel). 2023; 13(11).

PMID: 38004294 PMC: 10672417. DOI: 10.3390/life13112154.


Reducing brain kynurenic acid synthesis precludes kynurenine-induced sleep disturbances.

Rentschler K, Milosavljevic S, Baratta A, Wright C, Piroli M, Tentor Z J Sleep Res. 2023; 33(3):e14038.

PMID: 37678806 PMC: 10918043. DOI: 10.1111/jsr.14038.


Association of complement component 4 with neuroimmune abnormalities in the subventricular zone in schizophrenia and autism spectrum disorders.

Mou T, Lane M, Ireland D, Verthelyi D, Tonelli L, Clark S Neurobiol Dis. 2022; 173:105840.

PMID: 35995342 PMC: 9582995. DOI: 10.1016/j.nbd.2022.105840.


References
1.
Okuno E, Nakamura M, Schwarcz R . Two kynurenine aminotransferases in human brain. Brain Res. 1991; 542(2):307-12. DOI: 10.1016/0006-8993(91)91583-m. View

2.
Kozak R, Campbell B, Strick C, Horner W, Hoffmann W, Kiss T . Reduction of brain kynurenic acid improves cognitive function. J Neurosci. 2014; 34(32):10592-602. PMC: 6802596. DOI: 10.1523/JNEUROSCI.1107-14.2014. View

3.
Yu P, Mosbrook D, Tagle D . Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease. Mamm Genome. 1999; 10(9):845-52. DOI: 10.1007/s003359901102. View

4.
Guidetti P, Hoffman G, Melendez-Ferro M, Albuquerque E, Schwarcz R . Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia. 2006; 55(1):78-92. DOI: 10.1002/glia.20432. View

5.
Schwarcz R, Stone T . The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology. 2016; 112(Pt B):237-247. PMC: 5803785. DOI: 10.1016/j.neuropharm.2016.08.003. View